Abstract
This commentary refers to ‘Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD consortium’, by G.C.M. Siontis et al., https://doi.org/10.1093/eurheartj/ehad567 and the discussion piece ‘Randomised controlled trials remain underutilized’, by G.C.M. Siontis et al., https://doi.org/10.1093/eurheartj/ehad806.